Germany already had expanded access to treat other lower grade tumors being assigned under their HE program. No doubt this will happen quickly in the US and UK with their specials program as well. You are ignoring that rGBM is a given based on data which almost doubles the more immediate capacity need hence Cognate announcing their planned doubling of their cell therapy manufacturing capacity in January of last year after data lock and expected initial review of data by NWBO. Then Charles River Labs bought them and expanded beyond that. Underestimating the potential for others to see the platform and partnership worth (need) is also an underlying weakness in your assumptions about it. This will be presented to the market as validated science with commercial scale manufacturing in place. The ONLY reasons it hasn’t been so far is that NWBO has not made any formal statement about data and those who want more shares can’t get them cheap enough. Those $5 shares you talk about will disappear in an instant with uplisting. Care to guess when that might happen?; ). Best wishes.
Market Data 
Markets 
AI
